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Background: Azithromycin has been proposed as a treatment for COVID-19 on the 24 
basis of its immunomodulatory actions. We evaluated the efficacy and safety of 25 
azithromycin in hospitalised patients with COVID-19. 26 
Methods: In this randomised, controlled, open-label, adaptive platform trial, several 27 
possible treatments were compared with usual care in patients hospitalised with 28 
COVID-19 in the UK. Eligible and consenting patients were randomly allocated to either 29 
usual standard of care alone or usual standard of care plus azithromycin 500 mg once 30 
daily by mouth or intravenously for 10 days or until discharge (or one of the other 31 
treatment arms). Patients were twice as likely to be randomised to usual care as to any 32 
of the active treatment groups. The primary outcome was 28-day mortality. The trial is 33 
registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). 34 
Findings: Between 7 April and 27 November 2020, 2582 patients were randomly 35 
allocated to receive azithromycin and 5182 patients to receive usual care alone. Overall, 36 
496 (19%) patients allocated to azithromycin and 997 (19%) patients allocated to usual 37 
care died within 28 days (rate ratio 1·00; 95% confidence interval [CI] 0·90-1·12; 38 
p=0·99). Consistent results were seen in all pre-specified subgroups of patients. There 39 
was no difference in duration of hospitalisation (median 12 days vs. 13 days) or the 40 
proportion of patients discharged from hospital alive within 28 days (60% vs. 59%; rate 41 
ratio 1·03; 95% CI 0·97-1·10; p=0·29). Among those not on invasive mechanical 42 
ventilation at baseline, there was no difference in the proportion meeting the composite 43 
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endpoint of invasive mechanical ventilation or death (21% vs. 22%; risk ratio 0·97; 95% 44 
CI 0·89-1·07; p=0·54).  45 
Interpretation: In patients hospitalised with COVID-19, azithromycin did not provide 46 
any clinical benefit. Azithromycin use in patients hospitalised with COVID-19 should be 47 
restricted to patients where there is a clear antimicrobial indication. 48 
Funding: UK Research and Innovation (Medical Research Council) and National 49 
Institute of Health Research (Grant ref: MC_PC_19056).  50 
Keywords: COVID-19, azithromycin, clinical trial. 51 
 52 
NOTE: 53 
Enrolment to the azithromycin arm of the RECOVERY trial was closed on 27 November 54 
2020. Here we report the preliminary findings based on a data cut on 30 November 55 
2020. Final results will be made available after the last patient has completed the 28-56 
day follow-up period for the primary outcome on 25 December 2020. As with previous 57 
reports, we anticipate >99% follow-up of all patients due to the linkage with routine NHS 58 
data. With 1483 deaths among a total of 7764 patients included in the current report, the 59 
findings are unlikely to change in any material way. 60 
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INTRODUCTION  62 
A substantial proportion of individuals infected with severe acute respiratory syndrome 63 
coronavirus 2 (SARS-CoV-2) develop a respiratory illness requiring hospital care, which 64 
can progress to critical illness with hypoxic respiratory failure requiring prolonged 65 
ventilatory support. Among COVID-19 patients admitted to UK hospitals in the first wave 66 
of the epidemic, the case fatality rate was over 26%, and in excess of 37% in patients 67 
requiring invasive mechanical ventilation.1 68 
Among patients with severe COVID-19, the host immune response is thought to play a 69 
key role in driving an acute pneumonic process with diffuse alveolar damage, 70 
inflammatory infiltrates, and microvascular thrombosis.2 The beneficial effects of 71 
dexamethasone and other corticosteroids in patients with hypoxic lung damage suggest 72 
that other drugs that suppress or modulate the immune system may provide additional 73 
improvements in clinical outcomes.3,4 74 
Macrolide antibiotics, such as azithromycin, clarithromycin and erythromycin, are widely 75 
available and their safety is well established. In addition to antibacterial properties, they 76 
are known to have immunomodulatory activity, decreasing production of pro-77 
inflammatory cytokines and inhibiting neutrophil activation.5-7 They are widely used both 78 
in bacterial pneumonia due to their antimicrobial activity and in chronic inflammatory 79 
lung disease due to their immunomodulatory effects.8,9 In addition, azithromycin has in 80 
vitro antiviral activity against a range of viruses including SARS-CoV-2.10,11 81 
The use of macrolides in influenza-associated pneumonia has been associated with a 82 
faster reduction in inflammatory cytokines and, in combination with naproxen, 83 
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decreased mortality.12-14 However, randomised trials have so far failed to demonstrate 84 
convincing clinical benefit of macrolides in COVID-19.15-17 Here we report the 85 
preliminary results of a randomised controlled trial of azithromycin in patients 86 
hospitalised with COVID-19. 87 
 88 
METHODS 89 
Study design and participants 90 
The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-91 
initiated, individually randomised, controlled, open-label, adaptive platform trial to 92 
evaluate the effects of potential treatments in patients hospitalised with COVID-19. 93 
Details of the trial design and results for other possible treatments (dexamethasone, 94 
hydroxychloroquine, and lopinavir-ritonavir) have been published previously.3,18,19 The 95 
trial is underway at 176 hospitals in the United Kingdom (appendix pp 2-22), supported 96 
by the National Institute for Health Research Clinical Research Network. The trial is 97 
coordinated by the Nuffield Department of Population Health at the University of Oxford 98 
(Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles 99 
of the International Conference on Harmonisation–Good Clinical Practice guidelines and 100 
approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) 101 
and the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol, 102 
statistical analysis plan, and additional information are available on the study website 103 
www.recoverytrial.net. 104 
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Although the azithromycin, dexamethasone, hydroxychloroquine, and lopinavir-ritonavir 105 
arms have now been stopped, the trial continues to study the effects of tocilizumab, 106 
convalescent plasma, REGEN-COV2 (a combination of two monoclonal antibodies 107 
directed against SARS-CoV-2 spike glycoprotein), aspirin, and colchicine. Other 108 
treatments may be studied in future. 109 
Patients admitted to hospital were eligible for the study if they had clinically suspected 110 
or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the 111 
opinion of the attending clinician, put the patient at significant risk if they were to 112 
participate in the trial. Initially, recruitment was limited to patients aged at least 18 years 113 
but from 9 May 2020, the age limit was removed. Patients with known prolonged QTc 114 
interval or hypersensitivity to a macrolide antibiotic and those already receiving 115 
chloroquine or hydroxychloroquine were excluded from being randomised between 116 
azithromycin and usual care. Written informed consent was obtained from all patients, 117 
or a legal representative if they were too unwell or unable to provide consent.  118 
Randomisation and masking 119 
Baseline data were collected using a web-based case report form that included 120 
demographics, level of respiratory support, major comorbidities, suitability of the study 121 
treatment for a particular patient, and treatment availability at the study site (appendix 122 
pp 26-28). Eligible and consenting patients were assigned to either usual standard of 123 
care or usual standard of care plus azithromycin or one of the other available 124 
RECOVERY treatment arms using web-based simple (unstratified) randomisation with 125 
allocation concealed until after randomisation (appendix pp 23-25). Randomisation to 126 
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usual care was twice that of any of the active arms the patient was eligible for (e.g. 2:1 127 
in favour of usual care if the patient was eligible for only one active arm, 2:1:1 if the 128 
patient was eligible for two active arms). For some patients, azithromycin was 129 
unavailable at the hospital at the time of enrolment or if a macrolide antibiotic was 130 
considered by the managing physician to be either definitely indicated or definitely 131 
contraindicated. These patients were excluded from the randomised comparison 132 
between azithromycin and usual care. Patients allocated to azithromycin were to 133 
receive azithromycin 500 mg by mouth, nasogastric tube, or intravenous injection once 134 
daily for 10 days or until discharge, if sooner. Allocated treatment was prescribed by the 135 
managing doctor. Participants and local study staff were not masked to the allocated 136 
treatment. The Steering Committee, investigators, and all others involved in the trial 137 
were masked to the outcome data during the trial. 138 
Procedures 139 
A single online follow-up form was completed when participants were discharged, had 140 
died or at 28 days after randomisation, whichever occurred earliest (appendix p 29-35). 141 
Information was recorded on adherence to allocated study treatment, receipt of other 142 
COVID-19 treatments, duration of admission, receipt of respiratory or renal support, and 143 
vital status (including cause of death). In addition, routine healthcare and registry data 144 
were obtained including information on vital status (with date and cause of death), 145 
discharge from hospital, receipt of respiratory support, or renal replacement therapy. 146 
Outcomes 147 
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Outcomes were assessed at 28 days after randomisation, with further analyses 148 
specified at 6 months. The primary outcome was all-cause mortality. Secondary 149 
outcomes were time to discharge from hospital, and, among patients not on invasive 150 
mechanical ventilation at randomisation, invasive mechanical ventilation (including 151 
extra-corporal membrane oxygenation) or death. Prespecified subsidiary clinical 152 
outcomes were cause-specific mortality, use of haemodialysis or haemofiltration, major 153 
cardiac arrhythmia (recorded in a subset), and receipt and duration of ventilation. 154 
Among those on invasive mechanical ventilation at randomisation, a subsidiary clinical 155 
outcome of successful cessation of invasive mechanical ventilation was defined as 156 
cessation within (and survival to) 28 days. Information on suspected serious adverse 157 
reactions was collected in an expedited fashion to comply with regulatory requirements. 158 
Statistical Analysis 159 
An intention-to-treat comparison was conducted between patients randomised to 160 
azithromycin and patients randomised to usual care but for whom azithromycin was 161 
both available and suitable as a treatment. For the primary outcome of 28-day mortality, 162 
the log-rank observed minus expected statistic and its variance were used to both test 163 
the null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the 164 
one-step estimate of the average mortality rate ratio. We constructed Kaplan-Meier 165 
survival curves to display cumulative mortality over the 28-day period. The 2059 166 
patients (27%) who had not been followed for 28 days and were not known to have died 167 
by the time of the data cut for this preliminary analysis (30 November 2020) were either 168 
censored on 30 November 2020 or, if they had already been discharged alive, were 169 
right-censored for mortality at day 29 (that is, in the absence of any information to the 170 
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contrary they were assumed to have survived 28 days). [Note: This censoring rule will 171 
not be necessary for the final report.] We used similar methods to analyse time to 172 
hospital discharge and successful cessation of invasive mechanical ventilation, with 173 
patients who died in hospital right-censored on day 29. Median time to discharge was 174 
derived from Kaplan-Meier estimates. For the pre-specified composite secondary 175 
outcome of invasive mechanical ventilation or death within 28 days (among those not 176 
receiving invasive mechanical ventilation at randomisation) and the subsidiary clinical 177 
outcomes of receipt of ventilation and use of haemodialysis or haemofiltration, the 178 
precise dates were not available and so the risk ratio was estimated instead.  179 
Prespecified analyses of the primary outcome were performed separately in seven 180 
subgroups defined by characteristics at randomisation: age, sex, ethnicity, level of 181 
respiratory support, days since symptom onset, use of corticosteroids, and predicted 182 
28-day mortality risk (appendix p 26). Observed effects within subgroup categories were 183 
compared using a chi-squared test for heterogeneity or trend, in accordance with the 184 
prespecified analysis plan. 185 
Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values 186 
are 2-sided and are shown without adjustment for multiple testing. The full database is 187 
held by the study team which collected the data from study sites and performed the 188 
analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, 189 
UK).  190 
As stated in the protocol, appropriate sample sizes could not be estimated when the trial 191 
was being planned at the start of the COVID-19 pandemic (appendix p 26). As the trial 192 
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progressed, the trial steering committee, whose members were unaware of the results 193 
of the trial comparisons, determined that sufficient patients should be enrolled to provide 194 
at least 90% power at a two-sided p-value of 0.01 to detect a clinically relevant 195 
proportional reduction in the primary outcome of 20% between the two groups. 196 
Consequently, on 27 November 2020, the steering committee, blinded to the results, 197 
closed recruitment to the azithromycin comparison as sufficient patients had been 198 
enrolled. 199 
Analyses were performed using SAS version 9.4 and R version 3.4.0. The trial is 200 
registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936). 201 
Role of the funding source 202 
The funder of the study had no role in study design, data collection, data analysis, data 203 
interpretation, or writing of the report. The corresponding authors had full access to all 204 




Between 7 April 2020 and 27 November 2020, 9434 (57%) of 16443 patients enrolled 209 
into the RECOVERY trial were eligible to be randomly allocated to azithromycin (that is 210 
azithromycin was available in the hospital at the time and the attending clinician was of 211 
the opinion that the patient had no known indication for or contraindication to 212 
azithromycin, figure 1; appendix p 38). 2582 patients were randomly allocated to 213 
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azithromycin and 5182 were randomly allocated to usual care, with the remainder being 214 
randomly allocated to one of the other treatment arms. The mean age of study 215 
participants in this comparison was 65·3 years (SD 15·7) and the median time since 216 
symptom onset was 8 days (IQR 5 to 11 days) (table 1; appendix p 38).  217 
Among the 5910 (76%) patients for whom a follow-up form has been completed to date, 218 
1760 (89%) allocated to azithromycin vs. 55 (1%) allocated to usual care received at 219 
least one dose, and 1836 (92%) vs. 606 (15%) received any macrolide antibiotic (figure 220 
1; appendix p 39). The median duration of treatment with azithromycin was 6 days (IQR 221 
3-9 days). Use of other treatments for COVID-19 was similar among patients allocated 222 
azithromycin and among those allocated usual care, with nearly one half receiving a 223 
corticosteroid, about one-fifth receiving remdesivir, and one-fifth receiving convalescent 224 
plasma. 225 
We observed no significant difference in the proportion of patients who met the primary 226 
outcome of 28-day mortality between the two randomised groups (496 [19%] patients in 227 
the azithromycin group vs. 997 (19%) patients in the usual care group; rate ratio 1·00; 228 
95% confidence interval [CI], 0·90 to 1·12; p=0·99; figure 2). We observed similar 229 
results across all pre-specified subgroups (figure 3). In an exploratory analysis restricted 230 
to the 6916 (89%) patients with a positive SARS-CoV-2 test result, the result was similar 231 
(rate ratio 0·99, 95% CI 0·88 to 1·10; p=0·81).  232 
Allocation to azithromycin was associated with a similar time until discharge from 233 
hospital alive as usual care (median 12 days vs. 13 days) and a similar probability of 234 
discharge alive within 28 days (60% vs. 59%, rate ratio 1·03, 95% CI 0·97 to 1·10, 235 
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p=0·29) (Table 2). Among those not on invasive mechanical ventilation at baseline, the 236 
number of patients progressing to the pre-specified composite secondary outcome of 237 
invasive mechanical ventilation or death among those allocated to azithromycin was 238 
similar to that among those allocated to usual care (21% vs. 22%, risk ratio 0·97, 95% 239 
CI 0·89 to 1·07, p=0·54). Allowing for multiple testing in interpretation of the results, 240 
there was no evidence that the effect of allocation to azithromycin vs. usual care on time 241 
until discharge from hospital alive or on invasive mechanical ventilation or death differed 242 
between pre-specified subgroups of patients (appendix p 43-44).  243 
We found no significant differences in the prespecified subsidiary clinical outcomes of 244 
cause-specific mortality (appendix p 40), use of ventilation, successful cessation of 245 
invasive mechanical ventilation, or need for renal dialysis or haemofiltration (Table 2). 246 
We observed no significant differences in the frequency of new cardiac arrhythmias 247 
(appendix p 41). There was one report of a serious adverse reaction believed related to 248 
azithromycin: a case of pseudomembranous colitis from which the patient recovered 249 
with standard treatment. 250 
 251 
DISCUSSION 252 
The results of this large randomised trial show that azithromycin is not an effective 253 
treatment for patients hospitalised with COVID-19. Allocation to azithromycin was not 254 
associated with reductions in mortality, duration of hospitalisation or the risk of being 255 
ventilated or dying for those not on ventilation at baseline. These results were 256 
consistent across the prespecified subgroups of age, sex, ethnicity, duration of 257 
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symptoms prior to randomisation, level of respiratory support at randomisation, use of 258 
corticosteroids, and baseline predicted risk of death at randomisation.  259 
Azithromycin was proposed as a treatment for COVID-19 based on its 260 
immunomodulatory activity.7 Although no major organization or professional society has 261 
recommended the routine use of azithromycin in COVID-19 unless there is evidence of 262 
bacterial super-infection, it has nevertheless been used widely in COVID-19 patients, 263 
particularly in combination with hydroxychloroquine.20-22 Macrolides have long been 264 
suggested as potential therapies for inflammatory viral pneumonias but this has been 265 
based on in vitro, animal and observational data, with very little clinical trial evidence of 266 
benefit.11-13 The benefit of dexamethasone in COVID-19 patients requiring respiratory 267 
support suggests that inflammation has a causal role in mortality.3 Noting that the 268 
results were consistent regardless of whether patients were also being treated with a 269 
corticosteroid or not, we conclude that the immunomodulatory properties of 270 
azithromycin are either insufficient or off-target in COVID-19.  271 
Macrolides are commonly used to treat bacterial infections of the lower respiratory tract 272 
because of their good activity against Gram positive bacteria and atypical pathogens 273 
such as Mycoplasma pneumoniae and Legionella species, and their excellent tissue 274 
penetration. More than 75% of hospitalised COVID-19 patients are prescribed 275 
antibiotics and the widespread clinical use of macrolides in COVID-19 is likely to be 276 
driven largely by concerns of bacterial superinfection rather than purported 277 
immunomodulatory activity.23 It is therefore important to highlight that in patients with 278 
moderate or severe COVID-19, who might be expected to experience some burden of 279 
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secondary bacterial lung infection, there was no observed clinical benefit of 280 
azithromycin use. This lack of effect may either reflect the relatively low rate of 281 
secondary bacterial infection in COVID-19 or the widespread use of other antibiotics 282 
such as β-lactam antibiotics, which may have abrogated any anti-bacterial benefit of 283 
allocation to azithromycin in this trial.24,25 Our results show that azithromycin confers no 284 
clinical benefit in hospitalised COVID-19 patients, whether that be anti-inflammatory or 285 
antimicrobial. Although we detected no harm to individual patients treated with 286 
azithromycin, there is a risk of harm at a societal level from widespread use of 287 
antimicrobial agents. Azithromycin is classified within the WHO Watch Group of 288 
Antibiotics: antibiotics that have higher resistance potential and should be prioritized as 289 
key targets of antimicrobial stewardship programs. In light of the new evidence from the 290 
RECOVERY trial, the widespread use in COVID-19 patients of macrolides in particular 291 
and antibiotics in general must be questioned.26  292 
Our trial has some limitations: Detailed information on laboratory markers of 293 
inflammatory status, co-existent bacterial infection, or use of non-macrolide antibiotics 294 
was not collected, nor was information on radiological or physiological outcomes. This 295 
initial report is based on complete follow-up for the primary outcome in 73% of patients 296 
(and partial follow-up for the remaining 27%). However, collection of outcome 297 
information both through case report forms and linkage to routine NHS records is 298 
ongoing and, based on previous reports from this trial, will deliver complete follow-up 299 
information for over 99% of patients by early January 2021. However, additional follow-300 
up is unlikely to change the conclusion that azithromycin has no meaningful benefit for 301 
hospitalised patients with COVID-19. 302 
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Three other randomised controlled trials have assessed the efficacy of azithromycin for 303 
the treatment of COVID-19 in hospitalised patients, all of which additionally treated 304 
patients with hydroxychloroquine.15-17 The COALITION I and COALITION II trials found 305 
that allocation of hospitalized patients with COVID-19 to azithromycin and 306 
hydroxychloroquine, was not associated with any improvement in mortality, duration of 307 
hospital stay, or clinical status as assessed using an ordinal outcome scale.15,16 A small 308 
trial in Iran that randomised patients to hydroxychloroquine and lopinavir-ritonavir with 309 
or without azithromycin also found no significant difference in mortality or intensive care 310 
unit admission, but suggested a reduction in duration of hospital stay.17 The total 311 
number of patients in all three prior trials combined was 1223, with 130 deaths. The 312 
RECOVERY trial, with 7764 participants and 1483 deaths in this assessment of 313 
azithromycin, is far better powered to detect modest treatment benefits; none were 314 
observed.  315 
At the time of writing, 24 trials evaluating the use of macrolides in COVID-19 patients 316 
were registered in the WHO International Clinical Trials Registry Platform, of which two 317 
(COALITION I and COALITION II, described above) have published results. Of the 318 
remaining 22, 16 are studying macrolides in inpatients either alone or in combination 319 
with other putative treatments, whilst 6 are studying non-hospitalised patients with 320 
suspected or confirmed COVID-19. 321 
Whilst our findings do not address the use of macrolides for the treatment of non-322 
hospitalised COVID-19 patients with early, mild disease, the results do show that 323 
azithromycin is not an effective treatment for hospitalised COVID-19 patients. 324 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted December 14, 2020. ; https://doi.org/10.1101/2020.12.10.20245944doi: medRxiv preprint 
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Committee, and approved by all members of the trial steering committee. PWH and MJL 328 
vouch for the data and analyses, and for the fidelity of this report to the study protocol 329 
and data analysis plan. PWH, MM, JKB, LCC, SNF, TJ, KJ, WSL, AM, KR, EJ, RH, and 330 
MJL designed the trial and study protocol. MM, AR, G P-A, CB, BP, DC, AU, AA, ST, 331 
BY, RB, SS, DM, RH, the Data Linkage team at the RECOVERY Coordinating Centre, 332 
and the Health Records and Local Clinical Centre staff listed in the appendix collected 333 
the data. ES, NS, and JRE did the statistical analysis. All authors contributed to data 334 
interpretation and critical review and revision of the manuscript. PWH and JL had 335 
access to the study data and had final responsibility for the decision to submit for 336 
publication.  337 
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Age, years 65.4 (15.6) 65.2 (15.7) 
<70* 1508 (58%) 3015 (58%) 
≥70 to <80 615 (24%) 1167 (23%) 
≥80 459 (18%) 1000 (19%) 
   
Sex   
Male 1603 (62%) 3216 (62%) 
Female† 979 (38%) 1966 (38%) 
   
Ethnicity   
White 1867 (72%) 3773 (73%) 
Black, Asian, and minority ethnic 363 (14%) 708 (14%) 
Unknown 352 (14%) 701 (14%) 
   
Number of days since symptom onset 8 (5-11) 8 (5-11) 
Number of days since admission to 
hospital 2 (1-4) 2 (1-4) 
   
Respiratory support received   
No oxygen received 490 (19%) 918 (18%) 
Oxygen only ‡ 1940 (75%) 3964 (76%) 
Invasive mechanical ventilation 152 (6%) 300 (6%) 
   
Previous diseases   
Diabetes 700 (27%) 1433 (28%) 
Heart disease 693 (27%) 1350 (26%) 
Chronic lung disease 621 (24%) 1314 (25%) 
Tuberculosis 3 (<1%) 16 (<1%) 
HIV 7 (<1%) 22 (<1%) 
Severe liver disease § 45 (2%) 65 (1%) 
Severe kidney impairment ¶ 155 (6%) 334 (6%) 
Any of the above 1507 (58%) 3014 (58%) 
   
Use of corticosteroids   
Yes 1567 (61%) 3172 (61%) 
No 183 (7%) 399 (8%) 
Unknown^ 832 (32%) 1611 (31%) 
   
Severe acute respiratory syndrome 
coronavirus 2 test result   
Positive 2282 (88%) 4634 (89%) 
Negative 195 (8%) 371 (7%) 
Unknown 105 (4%) 177 (3%) 
   
Data are mean (SD), n (%), or median (IQR). * Includes 26 children (<18 years).  
† Includes 25 pregnant women. ‡ Includes non-invasive ventilation. § Defined as 
requiring ongoing specialist care. ¶ Defined as estimated glomerular filtration rate <30 
mL/min per 1.73 m². ^ Information on use of corticosteroids was collected from 18 June 
2020 onwards following announcement of the results of the dexamethasone 
comparison from the RECOVERY trial. 
  583 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted December 14, 2020. ; https://doi.org/10.1101/2020.12.10.20245944doi: medRxiv preprint 
Azithromycin for COVID-19 
30 
 
Table 2: Effect of allocation to azithromycin on key study outcomes 584 
 
Treatment allocation 





     
Primary outcome:     
28-day mortality 496 (19%) 997 (19%) 1.00 (0.90-1.12) 0.99 
     
Secondary outcomes:     
Median time to being discharged alive, days 12 13   
Discharged from hospital within 28 days 1554 (60%) 3066 (59%) 1.03 (0.97-1.10) 0.29 
Receipt of invasive mechanical ventilation or death* 517/2430 (21%) 1069/4882 (22%) 0.97 (0.89-1.07) 0.54 
Invasive mechanical ventilation 154/2430 (6%) 325/4882 (7%) 0.95 (0.79-1.15) 0.60 
Death 442/2430 (18%) 891/4882 (18%) 1.00 (0.90-1.10) 0.95 
     
Subsidiary clinical outcomes     
Receipt of ventilation † 27/490 (6%) 50/918 (5%) 1.01 (0.64-1.59) 0.96 
Non-invasive ventilation 24/490 (5%) 43/918 (5%) 1.05 (0.64-1.70) 0.86 
Invasive mechanical ventilation 8/490 (2%) 11/918 (1%) 1.36 (0.55-3.37) 0.50 
Successful cessation of invasive mechanical 
ventilation ‡ 42/152 (28%) 95/300 (32%) 0.84 (0.59-1.20) 0.33 
Use of haemodialysis or haemofiltration § 79/2548 (3%) 158/5125 (3%) 1.01 (0.77-1.31) 0.97 
 
Data are n (%) or n/N (%), unless otherwise indicated. RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful 
cessation of invasive mechanical ventilation, and risk ratio for other outcomes. * Analyses exclude those on invasive mechanical ventilation 
at randomisation. † Analyses exclude those on any form of ventilation at randomisation. ‡ Analyses restricted to those on invasive 
mechanical ventilation at randomisation. § Analyses exclude those on haemodialysis or haemofiltration at randomisation. 
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Figure 1: Trial profile 561 
ITT=intention to treat. # Number recruited overall during period that adult participants 562 
could be recruited into azithromycin comparison. * 1986/2582 (77%) and 3924/5182 563 
(76%) patients have a completed follow−up form at time of analysis. 3994 patients were 564 
additionally randomised to convalescent plasma vs REGN−COV2 vs usual care (1320 565 
[51%] patients allocated to azithromycin vs 2674 [52%] patients allocated usual care) 566 
and 975 patients were additionally randomised to aspirin vs usual care (323 [13%] 567 
patients allocated to azithromycin vs 652 [13%] patients allocated usual care. † Includes 568 
197/2582 (7.6%) patients in the azithromycin arm and 446/5182 (8.6%) patients in the 569 
usual care arm allocated to tocilizumab.  570 
Figure 2: Effect of allocation to azithromycin on 28-day mortality 571 
Figure 3: Effect of allocation to azithromycin on 28-day mortality by baseline 572 
characteristics 573 
Subgroup−specific rate ratio estimates are represented by squares (with areas of the 574 
squares proportional to the amount of statistical information) and the lines through them 575 
correspond to the 95% CIs. The ethnicity and days since onset subgroups exclude 576 
those with missing data, but these patients are included in the overall summary 577 
diamond. * Includes patients receiving non−invasive ventilation. Information on use of 578 
corticosteroids was collected from 18 June 2020 onwards following announcement of 579 
the results of the dexamethasone comparison from the RECOVERY trial. 580 
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Figure 3: Effect of allocation to azithromycin on 28−day mortality
by baseline characteristics





Age, years (χ 1
2=
<70 154/1508 (10%) 271/3015 (9%) 1.16 (0.95−1.42) 
≥ 70 <80 176/615 (29%) 331/1167 (28%) 1.00 (0.83−1.21) 




Men 347/1603 (22%) 666/3216 (21%) 1.05 (0.92−1.20) 




White 402/1867 (22%) 786/3773 (21%) 1.04 (0.92−1.17) 
Black, Asian and Minority Ethnic 58/363 (16%) 126/708 (18%) 0.91 (0.67−1.23) 
0.6; p=0.42)
Days since symptom onset (χ 1
2=
≤ 7 264/1163 (23%) 534/2355 (23%) 1.01 (0.87−1.17) 
>7 232/1418 (16%) 458/2812 (16%) 1.01 (0.86−1.18) 
0.0; p=1.00)
Respiratory support at randomisation (χ 1
2=
No oxygen received 62/490 (13%) 111/918 (12%) 1.04 (0.76−1.43) 
Oxygen only* 380/1940 (20%) 780/3964 (20%) 1.00 (0.88−1.13) 
Invasive mechanical ventilation 54/152 (36%) 106/300 (35%) 1.01 (0.73−1.41) 
0.0; p=0.89)
Use of corticosteroids (χ 1
2=
Yes 268/1567 (17%) 535/3172 (17%) 1.03 (0.89−1.19) 
No 25/183 (14%) 54/399 (14%) 1.02 (0.63−1.64) 
Unknown 203/832 (24%) 408/1611 (25%) 0.95 (0.80−1.12) 
0.0; p=0.97)
Baseline risk (χ 1
2=
<30% 180/1718 (10%) 308/3389 (9%) 1.18 (0.97−1.42) 
≥ 30% <45% 162/523 (31%) 332/1058 (31%) 0.97 (0.81−1.18) 
≥ 45% 154/341 (45%) 357/735 (49%) 0.91 (0.75−1.10) 
3.5; p=0.06)
All participants 496/2582 (19%) 997/5182 (19%)
p=0.99
1.00 (0.90−1.12) 
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